CN111295387A - 杂芳基酰胺类化合物、其制备方法、药用组合物及其应用 - Google Patents

杂芳基酰胺类化合物、其制备方法、药用组合物及其应用 Download PDF

Info

Publication number
CN111295387A
CN111295387A CN201880071456.3A CN201880071456A CN111295387A CN 111295387 A CN111295387 A CN 111295387A CN 201880071456 A CN201880071456 A CN 201880071456A CN 111295387 A CN111295387 A CN 111295387A
Authority
CN
China
Prior art keywords
alkyl
piperidinyl
piperazinyl
substituted
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880071456.3A
Other languages
English (en)
Other versions
CN111295387B (zh
Inventor
任瑞宝
邓贤明
吴敏
张婷
焦波
康巧凤
黄伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yingshi Biotechnology Nanjing Co ltd
Yingshi Biotechnology Shanghai Co ltd
Original Assignee
Xiamen University
Ruinjin Hospital Affiliated to Shanghai Jiaotong University School of Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xiamen University, Ruinjin Hospital Affiliated to Shanghai Jiaotong University School of Medicine Co Ltd filed Critical Xiamen University
Publication of CN111295387A publication Critical patent/CN111295387A/zh
Application granted granted Critical
Publication of CN111295387B publication Critical patent/CN111295387B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

本发明涉及杂芳基酰胺类化合物、其制备方法、药用组合物及其应用；具体地，涉及一类具有广谱抗肿瘤活性的化合物，其制备方法、包含该化合物的药物组合物，以及这些化合物在制备用于治疗肿瘤的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (7)

  1. PCT国内申请，权利要求书已公开。
CN201880071456.3A 2017-11-03 2018-11-02 杂芳基酰胺类化合物、其制备方法、药用组合物及其应用 Active CN111295387B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201711069948.2A CN109748927A (zh) 2017-11-03 2017-11-03 杂芳基酰胺类化合物、其制备方法、药用组合物及其应用
CN2017110699482 2017-11-03
PCT/CN2018/113549 WO2019085978A1 (zh) 2017-11-03 2018-11-02 杂芳基酰胺类化合物、其制备方法、药用组合物及其应用

Publications (2)

Publication Number Publication Date
CN111295387A true CN111295387A (zh) 2020-06-16
CN111295387B CN111295387B (zh) 2022-12-06

Family

ID=66332837

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201711069948.2A Pending CN109748927A (zh) 2017-11-03 2017-11-03 杂芳基酰胺类化合物、其制备方法、药用组合物及其应用
CN201880071456.3A Active CN111295387B (zh) 2017-11-03 2018-11-02 杂芳基酰胺类化合物、其制备方法、药用组合物及其应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201711069948.2A Pending CN109748927A (zh) 2017-11-03 2017-11-03 杂芳基酰胺类化合物、其制备方法、药用组合物及其应用

Country Status (8)

Country Link
US (1) US20200325156A1 (zh)
EP (1) EP3705481A4 (zh)
KR (1) KR20200112810A (zh)
CN (2) CN109748927A (zh)
AU (1) AU2018359934A1 (zh)
CA (1) CA3084846A1 (zh)
RU (1) RU2020118133A (zh)
WO (1) WO2019085978A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3151407A1 (en) * 2019-09-26 2021-04-01 Takushi Kaneko Indole carboxamide compounds and use thereof for the treatment of mycobacterial infections
JP2022549881A (ja) * 2019-09-26 2022-11-29 ザ グローバル アライアンス フォー ティービー ドラッグ デベロップメント， インコーポレイテッド マイコバクテリア感染症の処置のためのチアゾールカルボキサミド化合物およびその使用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101001861A (zh) * 2004-08-19 2007-07-18 安万特药物公司 作为酪蛋白激酶Iε抑制剂的被取代的噻吩并吡咯甲酸酰胺、吡咯并噻唑甲酸酰胺以及相关类似物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008001631A1 (es) * 2007-06-06 2009-01-02 Smithkline Beecham Corp Compuestos derivados de heterociclos sustituidos, con la presencia de un grupo fenoxi, inhibidores de transcriptasa inversa; composicion farmaceutica; y uso en el tratamiento de infecciones virales por vih.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101001861A (zh) * 2004-08-19 2007-07-18 安万特药物公司 作为酪蛋白激酶Iε抑制剂的被取代的噻吩并吡咯甲酸酰胺、吡咯并噻唑甲酸酰胺以及相关类似物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SARTORI, LURA ET AL: "thieno[3,2-b]pyrrole-5-carboxamides as new reversible inhibitors of histone lysine demethylase KDM1A/LSD1.PART 1.HIGH-THROUGHPUT screening and reliminary exploration", 《JOURNAL OF MEDICINAL CHEMISTRY》 *
STN REGISTRY: "《CAS RN 1934648-57-3》", 19 June 2016 *

Also Published As

Publication number Publication date
WO2019085978A1 (zh) 2019-05-09
AU2018359934A1 (en) 2020-06-18
CN111295387B (zh) 2022-12-06
RU2020118133A (ru) 2021-12-03
CN109748927A (zh) 2019-05-14
EP3705481A4 (en) 2021-09-01
CA3084846A1 (en) 2019-05-09
US20200325156A1 (en) 2020-10-15
EP3705481A1 (en) 2020-09-09
KR20200112810A (ko) 2020-10-05

Similar Documents

Publication Publication Date Title
JP7050093B2 (ja) 置換５員および６員複素環式化合物、その調製方法、薬剤の組み合わせおよびその使用
CN107151250B (zh) 嘧啶类七元环化合物、其制备方法、药用组合物及其应用
CN113286794A (zh) Kras突变蛋白抑制剂
CN107698603B (zh) 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
CN110770234B (zh) 取代芳基醚类化合物、其制备方法、药用组合物及其应用
EP3626718A1 (en) Five- and six-membered aza-aromatic compound, preparation method therefor, pharmaceutical composition, and application
CN113717156B (zh) Egfr抑制剂、其制备方法及用途
CN113825754B (zh) 包括甲基和三氟甲基的双取代磺酰胺类选择性bcl-2抑制剂
CN111295387B (zh) 杂芳基酰胺类化合物、其制备方法、药用组合物及其应用
CN109575045B (zh) 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
JP2023540083A (ja) 求核芳香族置換によるジオールの不斉化
JP7338896B2 (ja) Ｍｄｍ２阻害剤、その調製方法、医薬組成物および応用
CN109641909A (zh) 雷帕霉素信号通路抑制剂的机理靶标及其治疗应用
CN109666022B (zh) 三氮唑衍生物及其制备方法和用途
TWI732748B (zh) 噻唑衍生物的製造方法
EP4083031A1 (en) Quinoline compound and application thereof
WO2016034634A1 (fr) Derives de n-aryl-2-amino-4-aryl-pyrimidines polyethers macrocycliques comme inhibiteurs de la ftl3 and jak
CN115916759A (zh) 取代喹唑啉类化合物、其制备方法、药物组合及应用
TW202311260A (zh) 含有亞磺醯亞胺基的atr抑制劑化合物
CN116253735A (zh) 嘧啶并嘧啶酮类化合物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210713

Address after: 201202 room 201-6, 2nd floor, 307 JIANGCHANG 3rd road, Jing'an District, Shanghai

Applicant after: Yingshi Biotechnology (Shanghai) Co.,Ltd.

Address before: 197 Ruijin 2nd Road, Huangpu District, Shanghai 200025

Applicant before: RUI JIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG University SCHOOL OF MEDICINE

Applicant before: XIAMEN University

Effective date of registration: 20210713

Address after: 211500 3rd floor, building D-2, building 16, Shuwu, No. 73, tanmi Road, Jiangbei new district, Nanjing, Jiangsu Province

Applicant after: Yingshi Biotechnology (Nanjing) Co.,Ltd.

Address before: 201202 room 201-6, 2nd floor, 307 JIANGCHANG 3rd road, Jing'an District, Shanghai

Applicant before: Yingshi Biotechnology (Shanghai) Co.,Ltd.

GR01 Patent grant
GR01 Patent grant